Re: think independently

Then lost me more on the millions who have died. Also lost me on blood clotting.

Here's a chart showing exactly how 200+ fully vaccinated (mRNA) and unvaccinated people respond to a (delta) covid infection, over time. The part after day 6 is when your antibodies clear the virus. With Delta, the vaccine has no benefit beyond keeping you out of a hospital or dying. Otherwise it has little impact on viral levels, or spreading the virus, as you can see.

And as you can't see, and would know if you studied this, the immune system suppression comes from the virus upon initial replication. Your immune system, vaccinated or not, does not know you're infected for 6 days. That's not the vaccine, that's covid doing that. And there are specific ORF mutations (heightened in delta) that cause that, and they're increasing further with delta sub-variants. COVID suppresses your immune system and has since day one. That's why it's still here, and we can't stop it. And that suppression is coded in the ORF3 sections of the covid genome, NOT in the spike protein, which is what our mRNA vaccines code for.

And if you want to read up on it, like really deep stuff, just Google...there's plenty of literature of covid interferon and innate immune system suppression. It's the biggest trick it has in its bag of tricks. It's one we can't beat either. The r0 of covid jumped from 2.5 to 7-8 not from the spike protein mutating to become that much more efficient, it happened when mutations in ORF occurred. 1,000 times the viral load helps spread more than 15% better transmission with a spike protein mutation. It's like changing the choke on your shotgun to give you a better chance at hitting a deer, or adding 1,000 times more buckshot and not changing the pattern. I'd take the second approach. That's what the virus is doing too.

https://www.google.com/search?q=covid+delta+ORF+interferon+innate+suppression&rlz=1C1CHBF_enUS917US917&oq=covid+delta+ORF+interferon+innate+suppression&aqs=chrome..69i57.11240j0j4&sourceid=chrome&ie=UTF-8

Tiggity®

Oculus Spirit [97703]

TigerPulse: 100%

Posts: 64842

Joined: 7/13/02

ct cutoff was at 50

Aug 23, 2021, 5:12 PM

https://www.medrxiv.org/content/10.1101/2021.07.28.21261295v1.full-text

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study

Objectives Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed but variants of concerns (VOCs) with mutations in the spike protein are worrisome, especially B.1.617.2 (Delta) which has rapidly spread across the world. We aim to study if vaccination alters virological and serological kinetics in breakthrough infections.

Methods We conducted a multi-centre retrospective cohort study of patients in Singapore who had received a licensed mRNA vaccine and been admitted to hospital with B.1.617.2 SARS-CoV-2 infection. We compared the clinical features, virological and serological kinetics (anti-nucleocapsid, anti-spike and surrogate virus neutralization titres) between fully vaccinated and unvaccinated individuals.

Results Of 218 individuals with B.1.617.2 infection, 84 had received a mRNA vaccine of which 71 were fully vaccinated, 130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p=0.001). PCR cycle threshold (Ct) values were similar between both vaccinated and unvaccinated groups at diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-spike protein antibodies was observed in vaccinated patients, however, these titers were significantly lower against B.1.617.2 as compared with the wildtype vaccine strain.

Conclusion The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust serological response. Vaccination remains a key strategy for control of COVID-19 pandemic.

### Competing Interest Statement

BEY reports personal fees from Roche and Sanofi, outside the submitted work. All other authors declare no competing interests.

### Funding Statement

This study was funded by grants from the Singapore National Medical Research Council (COVID19RF-001, COVID19RF-008). The funders had no role in the design and conduct of the study;url=https://www.medrxiv.org/content/10.1101/0.001). PCR cycle threshold (Ct) values were similar between both vaccinated and unvaccinated groups at diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-spike protein antibodies was observed in vaccinated patients, however, these titers were significantly lower against B.1.617.2 as compared with the wildtype vaccine strain.

Conclusion The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust serological response. Vaccination remains a key strategy for control of COVID-19 pandemic.

### Competing Interest Statement

BEY reports personal fees from Roche and Sanofi, outside the submitted work. All other authors declare no competing interests.

### Funding Statement

This study was funded by grants from the Singapore National Medical Research Council (COVID19RF-001, COVID19RF-008). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from study participants of the multi-centre study approved by National Healthcare Group Domain Specific Review Board (NHG-DSRB) (Study Reference 2012/00917). Informed consent for retrospective data collection at National Centre for Infectious Diseases (NCID) was waived (NHG-DSRB reference number 2020/01122).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.